Kidney & Cardiovascular Outcomes Similar Across GLP1s For Those With Type 2 Diabetes

Kidney and cardiovascular disease outcomes were similar among veterans with type 2 diabetes who were taking three types of glucagon-like peptide-1 receptor agonists (GLP-1s), according to a recent comparative effectiveness study. The comparison included liraglutide (brand names Saxenda and Victoza), semaglutide (brand names Ozempic, Wegovy, and Rybelsus), and dulaglutide (brand name Trulicity).

The comparison of three GLP-1 medications included 21,790 veterans with type 2 diabetes who could have some loss of kidney function, who did not have end-stage kidney disease. Within the group, 24.9% were taking liraglutide, 49.7% were taking semaglutide, and . . .